REFERENCES

REFERENCES

Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., ... & Tabrizi, S. J. (2015). Huntington disease. Nature Reviews Disease Primers, 1(1), 1-21. https://doi.org/10.1038/nrdp.2015.5 

Busse, M., Quinn, L., Debono, K., Jones, K., Collett, J., & Playfer, J. R. (2017). The role of specialized rehabilitation in the management of Huntington's disease. Journal of Huntington’s Disease, 6(3), 255-263. https://doi.org/10.3233/JHD-170258 

Frank, S. (2014). Tetrabenazine as anti-chorea therapy in Huntington disease: An open-label continuation study. BMC Neurology, 14(1), 168. https://doi.org/10.1186/s12883-014-0168-9 

MacDonald, M. E., Ambrose, C. M., Duyao, M. P., Myers, R. H., Lin, C., Srinidhi, L., ... & Gusella, J. F. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72(6), 971-983. https://doi.org/10.1016/0092-8674(93)90585-e 

Miller, J. R., Paulson, H. L., & Gonzalez-Alegre, P. (2008). Pathogenesis of Huntington's disease: The role of mitochondrial dysfunction and excitotoxicity. Journal of Clinical Investigation, 118(2), 515-526. https://doi.org/10.1172/JCI34265 

Phillips, K. (2024). Huntington Disease [PowerPoint slides]. Department of Neuroscience, Virginia Tech. 

Quarrell, O., O'Donovan, K. L., Bandmann, O., & Strong, M. (2009). The prevalence of juvenile Huntington's disease: A review of the literature and meta-analysis. PLoS Currents, 1, RRN1064. https://doi.org/10.1371/currents.RRN1064 

Ross, C. A., & Tabrizi, S. J. (2011). Huntington's disease: From molecular pathogenesis to clinical treatment. The Lancet Neurology, 10(1), 83-98. https://doi.org/10.1016/S1474-4422(10)70245-3

Shoulson, I., Kieburtz, K., & McDermott, M. P. (2017). Huntington disease: An evolving role for treatments and lifestyle in optimizing quality of life. JAMA Neurology, 74(4), 417-418. https://doi.org/10.1001/jamaneurol.2017.0025 

Tabrizi, S. J., Scahill, R. I., Owen, G., Durr, A., Leavitt, B. R., Roos, R. A., ... & Reilmann, R. (2019). Predicting disease progression in Huntington’s disease. The Lancet Neurology, 18(5), 483-495. https://doi.org/10.1016/S1474-4422(19)30063-0 

Vadasz, C., Kovacs, K., & Haacke, E. M. (2016). Lifestyle factors affecting progression of Huntington's disease: A review. Journal of Neurodegeneration, 3(1), 45-52. https://doi.org/10.1016/j.jneuro.2016.04.003 

Walker, F. O. (2007). Huntington's disease. The Lancet, 369(9557), 218-228. https://doi.org/10.1016/S0140-6736(07)60111-1 

Zheng, Z., & Diamond, M. I. (2012). Huntington disease and the huntingtin protein. Progress in Molecular Biology and Translational Science, 107, 189-214. https://doi.org/10.1016/B978-0-12-385883-2.00008-8 

IMAGES

Figure 1- Aetiology

Huntington Disease Aetiology. (2024). Created using Microsoft Copilot with the prompt “Huntington Disease Aetiology.”

Figure 2- Clinical Presentation

Huntington Disease Clinical Presentation. (2024). Created using Microsoft Copilot with the prompt “Huntington Disease.”

Figure 3- Treatments and Outlooks

Huntington Disease Treatment and Outlooks. (2024). Created using Microsoft Copilot with the prompt “Huntington Disease Treatment and Outlooks.”

Figure 4- Epidemiology

Huntington Disease Epidemiology. (2024). Created using Microsoft Copilot with the prompt “Huntington Disease Epidemiology.”

Figure 5- Looking Ahead

Huntington Disease Looking Ahead. (2024). Created using Microsoft Copilot with the prompt “Huntington Disease Looking Ahead.”